Stockreport

Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (A...

ZIOPHARM Oncology Inc  (ZIOP) 
Last ziopharm oncology inc earnings: 3/2 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ziopharm.com
PDF - Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers- Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20m [Read more]